Bitcoin Events will host the 10th Annual Edition of the Blockchain Africa Conference 2024 on November 20, 2024, at the CSIR International Convention Centre, Tshwane, South Africa. The Blockchain Africa Conference completes 10 years this year, covering 9500+ attendees with 350+ speakers spanning 160 countries. With its experience, knowledge and networking connections, Blockchain Africa Conference has established itself as a premier platform for bringing together the crypto community of Africa.

The event will see top blockchain leaders from the region and all across the globe presiding over speaker sessions. These global dignitaries will present real-world case studies and explore the current trends in the blockchain spectrum. The 30+ speakers will share their views and insights on the innovations, opportunities and challenges of the industry.

The conference agenda covers speaker sessions, workshops and panel discussions to an interactive crowd of over 500 participants. Together they will explore how evolving technologies like crypto and blockchain can change the landscape of business in Africa and all across the globe. The exhibitions will showcase the latest services, cutting-edge technologies, and pioneering and new brands dealing in blockchain and crypto.

Topics of discussion:

• Real-case studies on Blockchain in both financial and non-financial industries
• Cryptocurrency/digital asset regulation
• Hurdles in Blockchain technology

The main objective of the conference is to bring to light the hurdles faced by the blockchain community and the best ways to overcome them. Experts will further discuss the opportunities blockchain technology presents for Africa. The event offers a phenomenal networking opportunity to create business partnerships and collaborations, accelerating businesses in Africa. On November 22, the event will organize a networking session in Cape Town to foster interactions, connections and collaborations among attendees.

To learn more, please visit https://ibn.fm/RrSEw

Nexus Conference, an enterprise committed to shaping events that act as powerful conduits between buyers and sellers, is proud to announce the Digital Health Nexus Conference that will be held in London on November 14-15, 2024. This event aims to bring together leaders from pharma/biotech, universities, VC/investors, hospitals, and service providers, with various topics in discussion, including AI and technology and digitization in biotech.

This event will feature at least 20 speakers, among them Ismael Gauci, the Senior Director, Strategy & Business Enablement – Digital Health & Precision Medicine at Roche; Dave Harden, the Founder and Managing Partner at Outpost Ventures; and Marco Palladino, the head of global DPO and AI trust Counsel at Takeda. It looks to tackle industry challenges in the digital space, covering facets such as regulatory hurdles, the adoption of innovative healthcare practices, and data integration.

Attendees at the event are guaranteed to make meaningful industry connections. They can also be assured of staying in the loop with current trends, learning from leaders in the space and experts in the field. For them, this is an opportunity to connect with influencers and, in turn, their target audience, guaranteeing sales and potential partnerships. Lastly, attendees can be assured that they will leave the conference with fresh ideas and solutions for their businesses, particularly in an age where staying ahead of the curve is paramount.

The Digital Health Nexus Conference draws from Nexus Conference’s previous successful conferences, with a history of fostering ecosystems where innovation meets collaboration, and every conversation holds the potential to transform into a lasting partnership. For thousands of attendees, Nexus Conference events have been a way to network, grow, and redefine their business landscape, and the Digital Health Nexus Conference is no exception.

To learn more, please visit https://ibn.fm/Hhpg8

Get ready to discover incredible opportunities at the 20th Emerging Growth Equity Conference hosted by Noble Capital Markets on December 3rd and 4th at Florida Atlantic University. Join Kevin O’Leary, known as “Mr. Wonderful,” along with fellow Shark investors Daymond John and Robert Herjavec, as they meet with entrepreneurs and explore the next big investment opportunities.

This year’s conference will feature dozens of innovative public companies, showcasing groundbreaking ideas that can change the game. O’Leary and his colleagues have invested millions in startups that have collectively generated billions in sales, and they’re eager to discover the next wave of disruptors.

Don’t miss out on this exciting event that could introduce you to the next big success story! 

Find out why Kevin O’Leary thinks you can’t afford to miss NobleCon: https://youtu.be/fSDXzYYzMRY 

To register, visit: https://nobleconference.com

Industries, public and private investment firms, government agencies, banks, innovators, industry leaders, and non-profit organizations, are invited to the Sustain SoCal 15th Annual Energy Event on October 17, 2024, in Irvine, CA.

The event agenda comprises discussions, speaker sessions, roundtables, and one-on-one meetings among the company executives and investors. Startups in the sustainability and cleantech fields can leverage the reach and connections of the Sustain SoCal forum to gain visibility and market their innovative ideas among the industry giants.

Topics include:

• Electrification
• Agriculture
• Hydrogen
• Inflation Reduction Act
• Renewables
• Built environment
• Grant incentives
• Investor trends
• ESG
• Innovation

Leaders in the region will preside over speaker sessions, sharing insights on the status and progress of decarbonization solutions in the industrial, commercial and governmental sectors. The event will focus on local energy providers. Incentives, legislation and policies will be key points discussed at the conference.

Sustain SoCal events have been organized over the last 13 years to offer a strong networking forum for industry professionals from the public, private and academic sectors. Organizations of varying sizes participate, exchange ideas and collaborate to reach sustainable energy goals in the greater Southern California region.

Sustain SoCal has been key in researching, analyzing and implementing solutions for sustainability and cleantech in the greater Southern California region. They offer feasible solutions for challenges in the energy, water and transportation sectors created by growth, change and discrepancy issues in Southern California.

Cleantech startups receive assistance and guidance from the experts in the financial, legal, marketing, technology, and public policy sectors. Sustain SoCal community comprises newcomers and veteran cleantech companies, corporations, government organizations, schools, hospitals, nonprofits, and investors.

To learn more, please visit https://ibn.fm/oC6pS.

Pharma and biotech executives and professionals, service providers and allied agencies are invited to attend the BioPharma Formulation & Delivery Nexus on November 14-25, 2024, in London, UK.  Scientists, C-level executives, directors, and vice presidents from prestigious organizations in Europe and North America will attend the event. Industry leaders can harness the reach of the event platform to educate, learn and interact with an engaging audience from the BioPharma spectrum.

BioPharma Nexus is focused on creating a union among leading pharmaceutical and biotechnology entities, along with service providers. Their objective is to provide high-quality healthcare to patients all over the globe. At the BioPharma Nexus conferences, players can explore, discover and generate partnerships for scientific and healthcare collaborations.

London is the Mecca for global research, innovations and discoveries in the biotech arena. Leaders of the biotech & pharma sectors will attend the event to discuss useful insights on drug formulations and new approaches in delivery. They will share strategies to overcome challenges, emerging trends technologies, and advancements. The Biopharma Nexus is a viable platform for researchers, innovators, professionals, and service providers to engage in business deals and collaborations.

The event agenda is as:

• Discussion on the new modalities in drug development and formulations
• Innovative approach to drug delivery
• New developments in dosage forms
• Novel products, therapies, trends and technologies in drug formulation and delivery

The conference agenda includes discussion panels and keynote speaker sessions from industry experts, as well as presentations from new and established entities. During the networking breaks for drinks, food and entertainment, the attendees can mingle and interact for a better understanding of each other’s vision and working operations. The audience can meet the industry leaders, get their queries solved, and learn the latest trends in the drug formulation and discovery business.

To learn more, please visit https://ibn.fm/BUldQ.

MSLs serve as vital links between drug developers, healthcare managers, and opinion influencers in the biopharma industry. The quality and effectiveness of MSL work output can be more difficult to measure than those of other teams, but company management will nonetheless seek metrics to determine how MSLs are helping to advance commercial sales goals. Medical affairs team members need to be able to answer this question.

Dynamic Global Events’ fifth annual Next-Gen MSL Excellence Summit is designed to help MSLs enhance their engagement strategies, improve their business acumen and develop other soft skills that will lead to their teams’ success.

Topics featured include how to sync MSLs with clinical operations teams from the earliest stages of development, how to use AI to transform field insights, and how to identify the must-have components of emotional intelligence.

Attendees will find opportunities to connect with business professional targets to enhance and sustain their networks. Over the course of two days, they can anticipate a vibrant, insightful conference experience, located in the heart of the University of Pennsylvania’s Ivy League campus.

The university is a storied research institution, known as one of the nation’s first universities with a history dating back to the pre-Revolutionary War 1740s, and Philadelphia’s colonial-era history is on display in the surrounding community.

The Next-Gen MSL Excellence Summit will also include a livestream attendance option for those who seek its insights, but without the emphasis on networking and team-building that in-person attendance supplies.

Key takeaways: 

• Located on Philadelphia’s picturesque Ivy League campus
• Within walking distance of one of the nation’s most prestigious medical and educational centers and Philadelphia’s tourist spots
• Expert insights from speakers and panel discussions
• Opportunities for networking and group learning

For more information about this event and to register, please visit https://ibn.fm/gqi2Y.

Geoffrey Hinton, undeniably referred to as “the Godfather of AI,” has been awarded the Nobel Prize in Physics alongside John Hopfield for their groundbreaking work that triggered the development of machine learning, the science behind artificial intelligence as we know it today.

The duo got this global recognition for the foundational work that they did that made it possible for various AI applications and products to become a reality. Hinton, a University of Toronto-based computer scientist and his peer Hopfield, a Princeton University professor, shared a $1m cash prize that came with their coveted award. The ceremony recognizing the pair happened this Monday in Sweden.

When he was asked about the likely significance of the work they did to set the stage for the development of machine learning, Hinton strongly asserted that the science would have a huge societal influence comparable to the way the industrial revolution did. Explaining further he noted that while the industrial revolution set in motion a system that was superior to humans in terms of physical strength, the current revolution triggered by AI has the potential to exceed humans’ intellectual abilities.

Hinton foresees artificial intelligence revolutionizing various industries like healthcare in ways that will be a force multiplier for productivity.

Ellen Moons, who chairs the physics committee which selected the two as winners of the 2024 Nobel Prize, asserted that the work done by the individuals awarded has facilitated the integration of AI within the daily lives of humans. Moon added that because of what the laureates did, it is now possible to make critical decisions, such as medical diagnostic decisions, much faster and more reliably.

It should be noted that the transformative work of these two scientists was done about four decades ago. Hopfield was fascinated by the neural networks of the brain and wondered whether a similar physical system could be designed to mimic the brain’s function. He set to work to answer this question, and developed the computational nodes which were designed to function in the same way that neurons in the brain worked.

Synaptic connections within the brain make it possible for neurons to communicate with one another. Hopfield created connections to enable computational nodes to communicate with one another. Just as a human wracks their brain to recall a fact or some piece of information, AI nodes search through their repository of information to see patterns, “recall” information previously used or even come up with something new based it what the system had previously been taught.

After Hopfield’s work was published back in 1982, Hinton took it a step further to birth what we now know as machine learning.

Hopfield’s system was composed of a paltry 30 nodes that operated using approximately 500 connections. In comparison, ChatGPT, a generative AI system, has approximately a trillion parameters upon which it can generate the needed information a user requests it to produce.

As you can see, the AI systems today require a lot in terms of hardware such as microchips. Critical metals like copper, silver and gold have consequently seen rising demand to supply the rapidly growing AI industry. Opportunities are being created and numerous companies like McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) are positioned to reap the rewards of addressing this demand for “AI metals.”

For more information, visit the company’s website at www.McEwenMining.com

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

• Clene gave a fireside presentation and held one-on-one investor meetings at the 2024 Maxim Healthcare Virtual Summit on October 15.
• On October 30, Clene will give a presentation and participate in one-on-one meetings at The ThinkEquity Conference 2024 at the Mandarin Oriental Hotel in New York.
• Clene’s lead drug candidate, CNM-Au8^® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions.
• Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS and is scheduled to have a meeting with the FDA leadership in November.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) multiple sclerosis (“MS”) and Parkinson’s Disease (“PD”), is participating in two top investor conferences this month to present its latest achievements and key updates on its lead drug candidate, CNM-Au8 (https://ibn.fm/BDqtM).

On October 15, the company gave a fireside presentation at the 2024 Maxim Healthcare Virtual Summit. The October 15-17 event included presentations and interactive discussions with CEOs and key executives from a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies, along with several topical industry panels. Clene was also scheduled to take part in several one-on-one investor meetings with participants.

The company will also give a presentation and take part in one-on-one meetings at The ThinkEquity Conference 2024 at the Mandarin Oriental Hotel in New York on October 30, at 3:30 p.m. E.T. Those interested in attending can register at https://ibn.fm/Eycfv. This year’s ThinkEquity Conference will feature a diverse group of attendees, including U.S. public and private companies, Canadian and international listed companies, investors, and other industry professionals. Presentations at the event will cover investment topics across various sectors, including AI, biotechnology, metals and mining, oil and gas, and technology.

Developed as an oral suspension of gold nanocrystals, CNM-Au8 works by improving cellular energy production and utilization, which is critical for maintaining neuronal health. In both clinical trials and compassionate use programs, CNM-Au8 has already been shown to improve central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. By targeting mitochondrial dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of neurodegenerative conditions.

Clene’s lead drug candidate has obtained encouraging results in ALS patients in Phase 2 clinical trials RESCUE-ALS and HEALEY ALS Platform Trials, where participants who were administered CNM-Au8 saw significant improvement in survival rates and combined assessment of function and survival. In both trials CNM-Au8 treatment also delayed clinical worsening in ALS participants. Overall there is now more than 700 cumulative patient-years of safety data that show no significant safety concerns or safety trends identified as related to CNM-Au8 treatment.

The company is seeking to file a New Drug Application (“NDA”) using the accelerated approval regulatory pathway for CNM-Au8 for ALS and has already submitted biomarker and clinical efficacy data to the Food and Drug Administration. A meeting with the FDA leadership to discuss this request will be held in November. If this accelerated pathway is approved, the next steps will be to file an NDA by the end of the year and to launch a confirmatory global Phase 3 study in ALS.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Israel-based SuperCom has secured a new five-year contract for deploying its electronic monitoring tracking technology in the company’s home country, working with the Israel Prison Service state agency
• The contract will help the agency monitor an estimated 1,500 enrolled offenders
• SuperCom has been reporting an increasing number of contract wins in Europe and the U.S. this year to help public safety agencies track the movements of low-risk offenders
• Electronic monitoring programs are increasingly welcomed in nations working to reduce criminal recidivism and provide safety to domestic violence victims, helping agencies reduce their incarceration costs in the process

Electronic monitoring (“EM”) technology innovator SuperCom (NASDAQ: SPCB) recently secured a new contract with the Israel Prison Service state agency (“IPS”) to provide full-service EM capabilities for all electronically monitored criminal offender programs throughout the country.

SuperCom won the contract, already underway, in partnership with a nationwide security services provider through a competitive process that included several rounds of negotiations, demonstrations and system evaluations supervised by the IPS.

“We are deeply honored to support Israel’s public safety infrastructure during these challenging times,” SuperCom President and CEO Ordan Trabelsi stated in the news release announcing the contract (https://ibn.fm/G8NXX). “Our mission goes beyond business; it is about contributing to the safety and resilience of Israel.”

SuperCom’s PureSecurity Suite platform uses state-of-the-art GPS tracking technology that is monitored and used for further communication with appropriate authorities. It uses cutting-edge location technologies and sensors, an ultra-lightweight bracelet that can be worn inconspicuously by the offender while interacting with others at work or in other social settings, an advanced anti-tamper mechanism, the ability to interact seamlessly with other parties’ API (such as a user’s smartphone), multi-factor biometric sensors, and draws on extensive historical data for further analysis.

Israel’s prison system EM program has an estimated 1,500 people enrolled for monitoring.

“This win further enhances our ability to deliver top-tier technology and services for effectively managing correctional programs and enhancing public safety,” Trabelsi stated. “It highlights the growing demand for our advanced electronic monitoring solutions globally and strengthens our strategic position as a leading security technology provider.”

EM technology is gaining widespread acceptance in North America, Latin America and Europe as a means for reducing the costs of imprisonment for criminal offenders, allowing individuals to be at low risk of harming society to remain productive through employment and family interaction while meeting society’s needs for security by having their movements restricted and monitored to ensure the restrictions are enforced.

The market for EM products and services is a niche segment with a low number of competitors, making SuperCom’s opportunity potential stronger, particularly as it continues to build its reputation with a growing number of clients.

During recent months, SuperCom has secured five new contracts to provide domestic violence subject monitoring in Europe. The company has also reported new contracts in the United States — most recently with law enforcement agencies in West Virginia and New York.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• D-Wave has introduced service-level agreements (“SLAs”) for customers of its Leap quantum cloud service who are moving applications into production
• The Leap quantum cloud service offers 99.9% availability for its Solver API and aggregated set of annealing quantum computers
• The Leap quantum cloud service has seen a surge in usage over the past 12 months, with more than 60 million jobs submitted, a 215% increase over the previous 12 months

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, has introduced service-level agreements (“SLAs”) tailored for customers of its Leap quantum cloud service who are moving applications into production. According to a company news release, this move confirms D-Wave’s confidence in the Leap service’s availability, reliability, scalability, and ability to support commercial-grade quantum and hybrid-quantum application requirements (https://ibn.fm/mTrP0).

“As the transition to production deployments accelerates, providing exceptional access to our cloud service has never been more critical,” said Dr. Trevor Lanting, chief development officer at D-Wave. “Our SLA offering is designed to support this dynamic shift with confidence, enabling businesses to thrive as quantum technology’s commercial value and adoption grows.”

Providing real-time, secure access to D-Wave’s annealing quantum computers and hybrid solvers since its launch in 2018, the Leap quantum cloud service is a production-grade service that enables customers to run business-critical workflows.

According to D-Wave monitoring data, the service has consistently offered 99.9% availability for its Solver API and aggregated set of annealing quantum computers over the past two years, which indicates a high level of responsiveness even under heavy customer usage. Since its launch, the Leap service has run almost 200 million customer jobs without lengthy queue times, unavailable hardware workarounds or requiring advance work scheduled. The company also further enhanced the Leap service and Ocean(TM) SDK processing speeds by 30%, empowering customers to achieve faster computations and solve complex problems more effectively.

A testament to the growing demand for immediate access to cloud-based quantum computing, usage of the Leap quantum cloud service has increased by 215% in the last 12 months, with over 60 million jobs submitted in that time period. The increased usage also contributed to the decision to introduce SLAs for production customers. According to Heather West, PhD, research manager and analyst with IDC, organizations looking to incorporate quantum computing into their IT structure should consider opting for a real-time production-grade service that comes with the kind of assurances an SLA can provide. “Technology leaders should have the same expectations of quantum cloud services that they do for any software-as-a-service, with reliability and accessibility leading their decision criteria.” 

For more information, visit the company’s website at www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.